With 15.73 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.81 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $5.37 whereas the lowest price it dropped to was $4.78. The 52-week range on ATYR shows that it touched its highest point at $5.98 and its lowest point at $1.47 during that stretch. It currently has a 1-year price target of $19.35. Beta for the stock currently stands at 0.90.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ATYR was down-trending over the past week, with a drop of -3.64%, but this was up by 19.76% over a month. Three-month performance surged to 54.29% while six-month performance rose 48.82%. The stock gained 38.95% in the past year, while it has gained 244.52% so far this year. A look at the trailing 12-month EPS for ATYR yields -0.81 with Next year EPS estimates of -0.61. For the next quarter, that number is -0.18. This implies an EPS growth rate of 28.86% for this year and 0.45% for next year.
Float and Shares Shorts:
At present, 89.00 million ATYR shares are outstanding with a float of 86.06 million shares on hand for trading. On 2025-06-13, short shares totaled 13.64 million, which was 1532.9999999999998 higher than short shares on 1747267200. In addition to Dr. Sanjay S. Shukla M.D., M.S. as the firm’s President, CEO & Director, Ms. Jill M. Broadfoot CPA serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 0.69627 of ATYR’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, ATYR reported revenue of $0.0 and operating income of -$15773000.0. The EBITDA in the recently reported quarter was -$15390000.0 and diluted EPS was -$0.17.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With ATYR analysts setting a high price target of 35.0 and a low target of 9.0, the average target price over the next 12 months is 19.35. Based on these targets, ATYR could surge 595.83% to reach the target high and rise by 78.93% to reach the target low. Reaching the average price target will result in a growth of 284.69% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.9009 being high and -$0.92092 being low. For ATYR, this leads to a yearly average estimate of -$0.91091.
